Moderna (MRNA) Change in Cash (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Cash data on file, last reported at -$688.0 million in Q1 2026.

• On a quarterly basis, Change in Cash fell 127.06% year-over-year to -$688.0 million in Q1 2026; TTM through Mar 2026 was $283.0 million, a 163.6% increase from a year earlier, with the FY2025 full-year figure at $668.0 million, up 166.87% from the prior year.
• Change in Cash for Q1 2026 stood at -$688.0 million, down from $1.5 billion in the prior quarter.
• Over the last five years, Change in Cash for MRNA reached as high as $1.5 billion in Q4 2025 and fell as low as -$2.2 billion in Q2 2022.
• Historically, Change in Cash has averaged -$291.2 million across 5 years, with a median of -$147.0 million in 2025.
• Across the five-year window, Change in Cash plunged 1450.93% in 2022 and soared 1228.0% in 2024, its largest moves.
• Year by year, Change in Cash stood at $176.0 million in 2022, then slumped by 114.2% to -$25.0 million in 2023, then surged by 1228.0% to $282.0 million in 2024, then jumped by 418.79% to $1.5 billion in 2025, then plunged by 147.03% to -$688.0 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$688.0 million in Q1 2026, $1.5 billion in Q4 2025, and -$147.0 million in Q3 2025.